✦ LIBER ✦

A phase I study of Triapine®in combination with doxorubicin in patients with advanced solid tumors

✍ Scribed by William R. Schelman; Sherry Morgan-Meadows; Rebecca Marnocha; Fred Lee; Jens Eickhoff; Wei Huang; Marcia Pomplun; Zhisheng Jiang; Dona Alberti; Jill M. Kolesar; Percy Ivy; George Wilding; Anne M. Traynor

Publisher: Springer
Year: 2008
Tongue: English
Weight: 364 KB
Volume: 63
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-008-0890-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I and pharmacologic study of the

A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors

✍ A. S. T. Planting; P. Sonneveld; A. van der Gaast; A. Sparreboom; M. E. L. van d 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 253 KB

Sunitinib in combination with docetaxel

Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study

✍ Francisco Robert; Alan Sandler; Joan H. Schiller; Glenn Liu; Karen Harper; Lev V 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 233 KB

A phase I trial of gemcitabine in combin

A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors

✍ William Schelman; Sherry Morgan-Meadows; Howard Bailey; Kyle Holen; James P. Tho 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 325 KB

Sunitinib in combination with paclitaxel

Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results

✍ Elisabeth I. Heath; George R. Blumenschein; Roger B. Cohen; Patricia M. LoRusso; 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 210 KB

Phase I dose-escalation study of tezacit

Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors

✍ Johanna C. Bendell; Joseph P. Eder; Jeffrey W. Clark; Panagiotis Fidias; Thomas 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 3 views

Phase I clinical trial of bortezomib in

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors

✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi